Business
ImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New York
SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that chief executive officer Kristin Yarema, Ph.D., will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026 and management will participate in one-on-one meetings. Jefferies Global Healthcare Conference in New YorkDate: Thursday, June 4, 2026Time: 12:50 PM EDTWebcast: Linked here and archived for 90 days on events page on the Imagene IR website Ab
About this update from Imagenebio, Inc.
[{"type":"image","alt":"ImageneBio, Inc.","displaySize":"","headline":null,"caption":"ImageneBio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":126,"height":48,"url":"https://media.zenfs.com/en/globenewswire.com/8676856806afc907243b07503009d2bc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BwFWGXbnhNfM5RQw2jap0w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTgw/https://media.zenfs.com/en/globenewswire.com/8676856806afc907243b07503009d2bc","width":126,"height":48},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/BwFWGXbnhNfM5RQw2jap0w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTgw/https://media.zenfs.com/en/globenewswire.com/8676856806afc907243b07503009d2bc","width":126,"height":48}},"lazy":false},{"type":"text","content":"SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that chief executive officer Kristin Yarema, Ph.D., will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026 and management will participate in one-on-one meetings.","length":314,"tagName":"p"},{"type":"text","content":"Jefferies Global Healthcare Conference in New YorkDate: Thursday, June 4, 2026Time: 12:50 PM EDTWebcast: Linked here and archived for 90 days on events page on the Imagene IR website","length":195,"tagName":"p"},{"type":"text","content":"About ImageneBio, Inc. Imagene is a clinical-stage biotechnology company dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases with differentiated clinical profiles. The Company's program, IMG-007, is a receptor targeting, non-T cell-depleting, ADCC-silenced, anti-OX40 monoclonal antibody with an approximately 5-week half-life. Imagene is currently conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis. The Company has also completed a proof-of-concept trial and plans to initiate a Phase 2 study in alopecia areata.","length":625,"tagName":"p"},{"type":"text","content":"Company and Investor ContactRebecca [email protected]","length":64,"tagName":"p"},{"type":"text","content":"Media ContactJason Braco, PhDThe Health & Science [email protected]","length":92,"tagName":"p"},{"type":"text","content":"","length":0,"tagName":"p"}]